• Quince Therapeutics set a special shareholder meeting for Oct. 6, 2026 via live webcast.
• Vote planned on issuing common stock tied to conversion of Series C Non-Voting Convertible Preferred Stock, warrant exercises, and Orphai Options.
• Shareholders will also consider authorizing common stock issuance for the PIPE Preferred Shares and PIPE Warrants.
• Other items include increasing authorized common shares to 275,000,000, adopting a 2026 equity incentive plan, and a 2026 ESPP.
• Meeting may also seek approval to adjourn or postpone to continue soliciting votes on the share issuance and authorized share increase items.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quince Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-364220), on August 25, 2026, and is solely responsible for the information contained therein.